Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)

Inclusion Criteria: * Healthy Chinese infant 48 days to 63 days of age. * Infant's legally acceptable representative provides written informed consent for the study. Exclusion Criteria: * History of rotavirus disease, congenital gastrointestinal disorders, chronic diarrhea, failure to thrive, or abdominal surgery. * History of intussusception. * History of poliomyelitis. * Clinical evidence of active gastrointestinal illness. Note: Infants with gastroesophageal reflux disease \[GERD\] may participate in the study if the GERD is well controlled with or without medication. * Known or suspected impairment of immunological function, including severe combined immunodeficiency disease (SCID). * Has a fever, with an axillary temperature ≥37.5°C (or equivalent) at the time of vaccination or within 24 hours prior to vaccination. Note: The Visit 1 may be rescheduled after complete resolution of febrile illness. * Has acute disease. * Has underlying diseases such as cardiovascular, renal, liver, or blood disease. * History of known hypersensitivity to any components of rotavirus vaccine and/or IPV. * Uncontrolled epilepsy, encephalopathy, seizure, or other progressive neurological diseases. * Known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections. * Resides in a household with an immunocompromised person, including individuals with congenital immunodeficiency (including SCID), human immunodeficiency virus (HIV) infection, leukemia, lymph…